Skip to main content

Table 2 Molecular docking of Osthole and co-crystal ligands to targets proteins

From: Potential mechanisms of osthole against bladder cancer cells based on network pharmacology, molecular docking, and experimental validation

Compounds

Targets

Binding energy (kcal/mol)

PDB ID

Box size (x,y,z)

Osthole

MAPK1

-6.0

1TVO

(66,44,66)

Co-crystol ligand

MAPK1

-4.9

1TVO

(66,44,66)

Osthole

AKT1

-5.5

2UZS

(48,40,40)

Co-crystol ligand

AKT1

-1.7

2UZS

(48,40,40)

Osthole

HRAS

-5.6

121P

(40,40,44)

Co-crystol ligand

HRAS

-0.3

121P

(40,40,44)

Osthole

HSP90AA1

-4.7

1BYQ

(48,54,74)

Co-crystol ligand

HSP90AA1

-0.8

1BYQ

(48,54,74)

Osthole

PI3KR1

-5.3

1PIC

(48,40,40)

Co-crystol ligand

PI3KR1

-4.6

1PIC

(48,40,40)

Osthole

SRC

-3.6

1A07

(40,40,66)

Co-crystol ligand

SRC

-3.0

1A07

(40,40,66)